STD

Find Answers to The Questions on Everybody’s Mind on Health Channel’s Sex Talk Season 2

Retrieved on: 
星期二, 十一月 15, 2022
Libido, ED, Science, Health minister, Knowledge, App store, Partnership, App Store (iOS/iPadOS), SEX, Nova Southeastern University, Yoga, Fever (mixtape), CBD, Research, PBS, Element, Discovery Health Channel, Google Play, STD, Associate, Health

Miami, Florida, Nov. 15, 2022 (GLOBE NEWSWIRE) -- Miami, FL SEX TALK , a fan favorite, returns for a brand-new season on South Florida PBS's Health Channel.

Key Points: 
  • Miami, Florida, Nov. 15, 2022 (GLOBE NEWSWIRE) -- Miami, FL SEX TALK , a fan favorite, returns for a brand-new season on South Florida PBS's Health Channel.
  • This dynamic season includes insightful, on-camera interviews with medical experts and our brand-new Taking it to the streets segment.
  • Enjoy full episodes of Sex Talk before they hit the big screen by downloading the Health Channel App , available for download on Google Play and the App Store.
  • The 30-minute episodes of Sex Talk explore the science of sex, debunks sex misconceptions, and emphasize various elements of sexual wellness.

Global Syphilis Testing Market Report to 2028 - Increasing Government Funding or Investments on STD Testing is Driving Growth - ResearchAndMarkets.com

Retrieved on: 
星期一, 十一月 21, 2022
Infectious Diseases, Pharmaceutical, Health, Medical Devices, Patient, Investment, STD, Syphilis, Yaws, Pinta, NGO, Government, Human, Social media, Fear, Treponema pallidum, Rectum, Immune system, Chancre, Person, Disease, Location, Stigma, Sore, Health, Pharmaceutical industry, Risk management, Treponema

The "Global Syphilis Testing Market Size, Share & Industry Trends Analysis Report By Type, By Location of Testing testing), By Regional Outlook and Forecast, 2022 - 2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Syphilis Testing Market Size, Share & Industry Trends Analysis Report By Type, By Location of Testing testing), By Regional Outlook and Forecast, 2022 - 2028" report has been added to ResearchAndMarkets.com's offering.
  • The Global Syphilis Testing Market size is expected to reach $1.5 billion by 2028, rising at a market growth of 5.6% CAGR during the forecast period.
  • The early phase of syphilis is the concealed, or latent, stage, during which the patient is unaffected.
  • Utilizing the social media platforms and the various campaigns by the NGO and various authorities are making people aware about the Syphilis testing market.

Global Condom Market to Grow by $4.03 Billion During 2022-2026 - ResearchAndMarkets.com

Retrieved on: 
星期四, 十一月 17, 2022
Medical Supplies, Health, Prevalence, Condom, STD, Birth control, Retail

The "Global Condom Market 2022-2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Condom Market 2022-2026" report has been added to ResearchAndMarkets.com's offering.
  • The condom market is poised to grow by $4.03 bn during 2022-2026, accelerating at a CAGR of 9.31% during the forecast period.
  • The report on the condom market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
  • The condom market analysis includes distribution channel and material segments and geographic landscape.

Rhinostics and LVL technologies Partner to Provide Decapping Solutions for Automated Collection Device Workflows

Retrieved on: 
星期一, 十一月 14, 2022
Medical Supplies, Biotechnology, Other Health, Health, Oncology, Health Technology, Medical Devices, Research, Infectious Diseases, Genetics, Science, Automation, Workflow, Marketing, Inc., Swab, Genomics, Wyss Institute, Respiratory disease, Biotechnology, Partnership, Laboratory, PCR, Multimedia, Co-promotion, Doctor of Philosophy, Collection, VTM, Cancer, TLM, Biomarker, Research, ELISA, LVL, Harvard University, Genetic testing, SBS, COVID-19, Organization, NGS, STD, Gesellschaft mit beschränkter Haftung, Patient, 3D printing, Pharmaceutical industry, Medical device

By combining the Rhinostics sample collection device ingenuity with decapper technology, laboratories can benefit from an instantly scalable automated swab and small volume blood collection processing workflow.

Key Points: 
  • By combining the Rhinostics sample collection device ingenuity with decapper technology, laboratories can benefit from an instantly scalable automated swab and small volume blood collection processing workflow.
  • View the full release here: https://www.businesswire.com/news/home/20221114005373/en/
    Rhinostics and LVL technologies Partner to Provide Decapping Solutions for Automated Collection Device Workflows (Photo: Business Wire)
    Today, researchers, clinicians, and patients alike expect more when it comes to sample collection and diagnostic workflows from respiratory pathogens, sexually transmitted infections, genetic testing to cancer biomarkers and much more, explained Cheri Walker, PhD, President and CEO of Rhinostics.
  • Were excited to expand our partnership with LVL, our supplier of high-quality collection tubes to Rhinostics during the pandemic and beyond.
  • The LVL decapper instrument is the perfect complement to their consumables, allowing improvements to inefficient swab and blood collection workflows.

IMG Helps Commemorates World AIDS Day at Art Basel by Bridging the Gap Between Sex Education and Visual Art with National Recording Artist Trina

Retrieved on: 
星期四, 十一月 17, 2022
Hepatitis C, Wynwood Art District, Wynwood, Museum, HIV, Urban Health Resource Centre, HOT, Education, STD, Safe sex, World AIDS Day, Seoul Music Awards, ESPO, Medical device

IMGH has partnered with contemporary mural artist Stephen ESPO Powers to create a limited edition run of prints communicating three abstractmessages of safe sex.

Key Points: 
  • IMGH has partnered with contemporary mural artist Stephen ESPO Powers to create a limited edition run of prints communicating three abstractmessages of safe sex.
  • Sold exclusively on World AIDS Day at Wynwood's Museum of Graffiti , prints will be numbered and signed by ESPO with proceeds going to IMG Helps in support of core STD testing and treatment initiatives.
  • "Raising awareness for World AIDS Day with art and thought-provoking dialogue helps us to advance the sexual health conversation in a unique approach and in a comfortable environment."
  • IMG Helps, Inc. is a community clinic specializing in testing, treating, and managing HIV, Hepatitis C, STDs, PrEP treatment, and more.

FDA Approves Medicines360's LILETTA® (levonorgestrel-releasing intrauterine system) 52 mg to Prevent Pregnancy for up to Eight Years

Retrieved on: 
星期一, 十一月 14, 2022
SAN, Polyethylene, Internal bleeding, Endometritis, Body mass index, ACCESS, IUS, Pain, Infertility, Levonorgestrel, IUD, Population, PID, Woman, Obstetrics, Faecal calprotectin, Infection, Uterus, American Journal of Obstetrics and Gynecology, Abdominal pain, Risk, Safety, Sores, FDA, Pregnancy, Gynaecology, Ectopic pregnancy, Medicine, Fibroid, Department, HIV, Time, Barium sulfate, Birth certificate, University of Pennsylvania Health System, Vaginal bleeding, Multimedia, American Journal, Pelvic inflammatory disease, Hysterectomy, Death, Patient, Chills, Pelvic pain, Policy, Condom, CEO, BMI, Sex, STD, Allergy, Professor, AbbVie, Review, Perforation, Fever, Food, Shanda, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Birth control, Dietary supplement, Pharmaceutical industry

SAN FRANCISCO, Nov. 14, 2022 /PRNewswire/ -- Medicines360, a global nonprofit organization with a mission to expand women's access to quality medicines, announced today that the U.S. Food and Drug Administration (FDA) has approved Medicines360's Supplemental New Drug Application (sNDA) to extend the duration of use of Liletta® (levonorgestrel-releasing intrauterine system) 52 mg to prevent pregnancy for up to eight years. This approval is based on data from ACCESS IUS (A Comprehensive Contraceptive Efficacy & Safety Study of an IUS) that Medicines360 first published in the American Journal of Obstetrics and Gynecology in May 2022. With this FDA approval, LILETTA has one of the longest approved durations of use for a hormonal intrauterine device (IUD or IUS) in the U.S.

Key Points: 
  • LILETTA was approximately 99% effective in preventing pregnancy for up to eight years in a diverse population of women.
  • LILETTA is a hormone-releasing system placed in the uterus to prevent pregnancy for up to eight years.
  • LILETTA (levonorgestrel-releasing intrauterine system) 52mg is a hormone-releasing system placed in your uterus to prevent pregnancy for as long as you want for up to 8 years.
  • If you get pregnant while using LILETTA, you may have an ectopic pregnancy, which means the pregnancy is not in the uterus.

Lab-Away, A Bulgarian Provider of Medical Home Test Kits To Commemorate Its First Milestone

Retrieved on: 
星期三, 十一月 9, 2022
NCBI, STD, Health status of Asian Americans, Pandemic, COVID-19, Fertility, Safety, Confidentiality, Privacy, Patient, Life, EU, CEO, STI, Stigmata, Sexual abuse, Pharmaceutical industry

The healthcare e-commerce company is set to celebrate its first-year birthday on the 11th of November, 2022.

Key Points: 
  • The healthcare e-commerce company is set to celebrate its first-year birthday on the 11th of November, 2022.
  • Lab-Away is a EU-certified provider of medical home test kits for STDs / STIs, illegal substances abuse, and fertility / reproduction issues.
  • The Lab-Away home tests combine laboratory-grade of accuracy with a level of privacy and anonymity possible only when testing at home.
  • Lab-Away addresses these issues by making it possible for patients to test at the safety and privacy of their own homes.

binx health Announces Strategic Supply Agreement with Afaxys to Expand Sexual Health Test Access to Thousands of Clinics Nationally

Retrieved on: 
星期四, 十一月 10, 2022
Women, Other Science, Medical Supplies, FDA, General Health, Logistics, Supply Chain Management, Public Policy, Government, Consumer, Healthcare Reform, Medical Devices, Infectious Diseases, Health Technology, LGBTQ+, Transport, AIDS, University, Health, Education, State, Local, Science, CT, University, Pre-exposure prophylaxis, GPO, Gonorrhea, Health, Community, Sexually transmitted infection, HIV, Associated Press, FDA, Partnership, Risk, Binx, Organization, Technology, Diagnosis, NG, CDC, Man, Parenthood, Chlamydia, United, STD, Health equity, Patient, Public health, Health minister, Woman, STI, Infection, Group purchasing organization, Pharmaceutical industry, Birth control, Medical device

binx health, a healthcare technology and diagnostics company focused on making routine testing convenient, today announced a strategic agreement with Afaxys Group Services LLC to expand access to sexual health and wellness testing nationally through their Group Purchasing Organization (GPO) .

Key Points: 
  • binx health, a healthcare technology and diagnostics company focused on making routine testing convenient, today announced a strategic agreement with Afaxys Group Services LLC to expand access to sexual health and wellness testing nationally through their Group Purchasing Organization (GPO) .
  • Under the agreement, binx will offer its FDA-cleared, CLIA-waived point-of-care test for chlamydia (CT) and gonorrhea (NG) and its at-home digital health platform to thousands of clinics across the United States, under a preferred pricing model with joint marketing outreach among Afaxys and binx.
  • With this agreement, we will be able to help more patients receive the tests they need in a way that works best for them.
  • We applaud the important work of Afaxys and its member clinics in furthering healthcare access and are thrilled to join their GPO network, said Jeffrey Luber, Chief Executive Officer of binx health.

New Jersey Experts to Discuss Harm Reduction in Next Installment of Opioid Webinar Series

Retrieved on: 
星期一, 十一月 7, 2022
Mental health, Awareness, STD, Education, Addiction psychiatry, Opioid, GLOBE, Government, New Jersey Department of Health, Method, Heroin, Illegal drug trade, Naloxone, Rutgers University, Harm reduction, COVID-19, Division, HIV, South Orange/Maplewood Community Coalition on Race, Alcoholism, Public relations, New Jersey Division of Alcoholic Beverage Control, Organization, Partnership, Addiction, Puerto Rico Administration of Mental Health and Anti-Addiction Services, Advertising, Fentanyl, Data, Program, Communication, Drug, Pharmaceutical industry

The webinar, Saving Lives Harm Reduction and the Opioid Crisis, will be held at 11 a.m. Thursday, November 10.

Key Points: 
  • The webinar, Saving Lives Harm Reduction and the Opioid Crisis, will be held at 11 a.m. Thursday, November 10.
  • Harm reduction is an often misunderstood but important aspect of the fight against the opioid epidemic, PDFNJ Executive Director Angelo Valente said.
  • This webinar will provide New Jersey residents valuable education on naloxone and other methods of harm reduction.
  • This webinar will be the 11th in the 2022 Knock Out Opioid Abuse Day Learning Series .

CAN Community Health Names Dr. Steven Barnett Chief Medical Officer

Retrieved on: 
星期一, 十一月 7, 2022
Leadership, Family medicine, Hepatitis C, Medical director, Education, University of Connecticut Health Center, Pharmacy, Case management, STD, Yale University, Clemson University, Biology, University, Interim, Health, Mental health, University of Connecticut School of Medicine, Pleasure, Patient, MD, Medical device, Microbiology

SARASOTA, Fla., Nov. 7, 2022 /PRNewswire-PRWeb/ -- CAN Community Health (CAN) has appointed Steven Barnett, MD as Chief Medical Officer. Dr. Barnett joined the healthcare nonprofit in 2017 at its Columbia, South Carolina clinic. His role was later expanded to serve as Medical Director of CAN clinics in South Carolina, Virginia, and New Jersey. He has served as Interim Chief Medical Officer since August 2022. Dr. Barnett will step into his permanent role immediately, and beginning January 1, 2023, Dr. Barnett will also oversee all dental services provided by CAN.

Key Points: 
  • CAN Community Health (CAN) has appointed Steven Barnett, MD as Chief Medical Officer.
  • Dr. Barnett joined the healthcare nonprofit in 2017 and has served as Interim Chief Medical Officer since August 2022.
  • SARASOTA, Fla., Nov. 7, 2022 /PRNewswire-PRWeb/ -- CAN Community Health (CAN) has appointed Steven Barnett, MD as Chief Medical Officer.
  • He has served as Interim Chief Medical Officer since August 2022.